MA29459B1 - Vaccins - Google Patents

Vaccins

Info

Publication number
MA29459B1
MA29459B1 MA30387A MA30387A MA29459B1 MA 29459 B1 MA29459 B1 MA 29459B1 MA 30387 A MA30387 A MA 30387A MA 30387 A MA30387 A MA 30387A MA 29459 B1 MA29459 B1 MA 29459B1
Authority
MA
Morocco
Prior art keywords
vaccines
complexed
subunit
adjuvant
coli
Prior art date
Application number
MA30387A
Other languages
English (en)
Inventor
Marianne Dewerchin
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510280A external-priority patent/GB0510280D0/en
Priority claimed from GB0524407A external-priority patent/GB0524407D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA29459B1 publication Critical patent/MA29459B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION DE VACCIN COMPRENANT LA SOUS-UNITÉ B DE LA TOXINE THERMOLABILE D'E. COLI OU UN DÉRIVÉ DE CETTE DERNIÈRE PRÉSENTANT UNE HOMOLOGIE SUPÉRIEURE OU ÉGALE À 90 %, COMPLEXÉE AVEC UN ANTIGÈNE ET UN ADJUVANT
MA30387A 2005-05-19 2007-11-20 Vaccins MA29459B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0510280A GB0510280D0 (en) 2005-05-19 2005-05-19 Vaccines
GB0524407A GB0524407D0 (en) 2005-11-30 2005-11-30 Vaccines

Publications (1)

Publication Number Publication Date
MA29459B1 true MA29459B1 (fr) 2008-05-02

Family

ID=37431620

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30387A MA29459B1 (fr) 2005-05-19 2007-11-20 Vaccins

Country Status (13)

Country Link
US (1) US20090035330A1 (fr)
EP (1) EP1881844A2 (fr)
JP (1) JP2008540625A (fr)
KR (1) KR20080018201A (fr)
AU (1) AU2006248725A1 (fr)
BR (1) BRPI0610061A2 (fr)
CA (1) CA2608979A1 (fr)
EA (1) EA200702254A1 (fr)
IL (1) IL187008A0 (fr)
MA (1) MA29459B1 (fr)
MX (1) MX2007014390A (fr)
NO (1) NO20075727L (fr)
WO (1) WO2006123155A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (fr) * 2001-02-01 2002-08-07 Institut Curie Support universel pour le ciblage de molécules sur des cellules exprimant le récepteur Gb3
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE534661T1 (de) 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
EP2034022A1 (fr) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Récepteur de la lipocaline soluble liant le leukotriène B4 issu de Ixodes ricinus
EP2045263A1 (fr) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification et caractérisation moléculaire de métalloprotéases salivaires exprimées dans les glandes salivaires de la tique
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
MX2011013566A (es) * 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
AR077636A1 (es) 2009-07-08 2011-09-14 Abbott Biologicals Bv Vacuna viral y uso de la misma
WO2015089707A1 (fr) 2013-12-16 2015-06-25 财团法人农业科技研究所 Plasmide, procédé et kit de production de sous-unité b de l'entérotoxine instable à la chaleur
KR20170040305A (ko) * 2014-08-08 2017-04-12 이데미쓰 고산 가부시키가이샤 돼지 번식·호흡 장해 증후군 방제제
US10537626B2 (en) 2014-10-07 2020-01-21 Cytlimic Inc. HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
JP6898225B2 (ja) 2015-03-09 2021-07-07 サイトリミック株式会社 Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3797794A1 (fr) * 2015-04-07 2021-03-31 Cytlimic Inc. Médicament comprenant un agoniste au recepteur toll like 3 et une proteine lag-3
AU2017342189B2 (en) 2016-10-11 2023-09-21 Nec Corporation Medicine
CN111333734B (zh) * 2020-03-31 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种百日咳丝状血凝素融合蛋白及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5843464A (en) * 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6764840B2 (en) * 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines

Also Published As

Publication number Publication date
CA2608979A1 (fr) 2006-11-23
AU2006248725A1 (en) 2006-11-23
BRPI0610061A2 (pt) 2016-11-29
IL187008A0 (en) 2008-02-09
EP1881844A2 (fr) 2008-01-30
WO2006123155A2 (fr) 2006-11-23
US20090035330A1 (en) 2009-02-05
KR20080018201A (ko) 2008-02-27
MX2007014390A (es) 2008-02-12
EA200702254A1 (ru) 2008-06-30
WO2006123155A3 (fr) 2007-07-19
NO20075727L (no) 2008-02-15
JP2008540625A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
NO20075727L (no) Vaksineblanding omfattende B-subenhet av et E.coli varmetoksin og et antigen og en adjuvans
DE602004020189D1 (de) Adjuvante influenza-vakzine
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
WO2004014418A3 (fr) Composition vaccinale
MA30065B1 (fr) Vaccin
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
NZ621834A (en) Novel adjuvant compositions
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
EP1326633A4 (fr) Composition comprenant des microparticules immunogenes
MA30716B1 (fr) Vaccin
WO2005097211A3 (fr) Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation
WO2006065553A3 (fr) Vaccins glycoconjugues contenant un peptidoglycane
WO2005112991A3 (fr) Vaccins
WO2006042149A3 (fr) Determination et reduction de l'immunoresistance a la therapie de la toxine botulinique a l'aide de peptides de la toxine botulinique de type a
ATE308992T1 (de) Attenuierte bakterien verwendbar als impstoffe
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
MA45283A1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
SG147465A1 (en) Vaccine
WO2005013898A3 (fr) Nouvelles cibles et compositions destinees a etre utilisees dans la decontamination, l'immunoprophylaxie et le traitement post-exposition contre l'anthrax
GB2444676A (en) Adjuvanted vaccine
ATE399532T1 (de) Medizinische seife
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante